Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Drops By 37.4%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 313,600 shares, a decrease of 37.4% from the February 13th total of 500,700 shares. Based on an average daily volume of 3,190,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.0% of the shares of the company are sold short.

Cumberland Pharmaceuticals Stock Performance

Shares of NASDAQ:CPIX traded down $0.03 on Friday, hitting $5.46. The company’s stock had a trading volume of 45,268 shares, compared to its average volume of 862,303. Cumberland Pharmaceuticals has a 12 month low of $1.04 and a 12 month high of $7.25. The company has a market capitalization of $76.67 million, a price-to-earnings ratio of -7.09 and a beta of -0.19. The stock’s 50-day moving average is $4.07 and its two-hundred day moving average is $2.37. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.99 and a current ratio of 1.13.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Institutional Trading of Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP increased its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,649 shares of the specialty pharmaceutical company’s stock after buying an additional 18,271 shares during the quarter. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 15.51% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.